ClinicalTrials.gg
CompletedNCT07266792Updated Dec 5, 2025

Bioequivalence Study to Compare Brexpiprazole 4 mg Film Coated Tablets Versus RXULTI 4 mg Film Coated Tablet (Brexpiprazole)

A Phase 1 interventional study of Brexpiprazole Film Coated Tablets and RXULTI film coated tablet in Schizophrenia, sponsored by Humanis Saglık Anonim Sirketi. Completed at 1 site in India. Open to participants aged 45 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by Humanis Saglık Anonim Sirketi · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jun 2025, registered Dec 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
45 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.

Enrollment
24th of 28
36 · median 155
Started
2025
the only one that year
Phase 1
8 of 28
1 open now
Registered
27th of 28
by date
Lead sponsor
1 of 28
Humanis Saglık Anonim Sirketi

Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 24th largest by enrollment, is the only one that started in 2025, is one of 8 in phase 1, and was the 27th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 45 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing brexpiprazole in Schizophrenia, or all of them as a file.
02

Study summary

Single dose oral bioequivalence study of Brexpiprazole 4 mg Film Coated Tablets and RXULTI® (Brexpiprazole) 4 mg film-coated tablets in healthy adult human subjects under fasting conditions.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 45 to 65 years old, both inclusive.
  • Gender: Male and/or non-pregnant, non-lactating female.
  • A. Female of had a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test performed within 28 days of the first dose of study medication. They must use an acceptable form of . For female of child-bearing potential, acceptable forms of contraception included the following:
  • i. Non hormonal intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study period, or
  • ii. Barrier methods containing or used in conjunction with a spermicidal agent, or
  • iii. Surgical sterilization or
  • iv. Practicing sexual abstinence throughout the course of the study.
  • B. Female were not considered of child-bearing potential if one of the following was reported and documented on the medical history:
  • i. with spontaneous amenorrhea for at least one year, or
  • ii. Spontaneous amenorrhea for more than 6 months and less than one year with Serum Follicular Stimulating Hormone (FSH) level > 40 mIU/mL, or
  • iii. Bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, or
  • iv. Total hysterectomy and an absence of bleeding for at least 3 months.
  • 3) : 18.5 to 30.0 kg/m2, both inclusive; BMI value should be rounded off to one significant digit after decimal point (e.g. 30.04 rounds down to 30.0, while 18.45 rounds up to 18.5).
  • 4) Non-smokers and non-tobacco user (i.e. had no past history of smoking and tobacco consumed for at least one year prior to study).
  • 5) Was able to communicate effectively with study personnel.
  • 6) Was willing to provide written to participate in the study.
  • 7) All volunteers were judged by the principal or sub-investigator or physician as normal and healthy during a pre-study safety assessment performed within 28 days of the first dose of study medication which included:
  • a) A physical examination (clinical examination) with no finding.
  • No additional tests and/or examinations were performed.
  • All results were assessed against the current laboratory normal ranges at the time of testing and a copy of the normal ranges used was included in the study documentation.

Exclusion criteria

Exclusion Criteria:

  • 1) Had history of allergic responses to Brexpiprazole or other related drugs, or any of its formulation ingredients.
  • 2) Had significant diseases or abnormal findings during screening [medical history, physical examination (clinical examination), laboratory evaluations, recording, gynecological history and examination (including pelvic examination and routine breast examination) (for female volunteers)].
  • 3) Any disease or condition like diabetes, psychosis or others, which might compromise the haemopoietic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, Central nervous system or any other body system.
  • 4) Had history or presence of bronchial asthma.
  • 5) Used any hormone replacement therapy within 3 months prior to the first dose of study medication.
  • 6) Used any depot injection or implant of any drug within 3 months prior to the first dose of study medication.
  • 7) Used CYP enzyme inhibitors or inducers within 30 days prior to the first dose of study medication (see https://drug-interactions.medicine.iu.edu/MainTable.aspx).
  • 8) Had history or evidence of drug dependence or of alcoholism or of moderate alcohol use.
  • 9) Had history of difficulty with donating blood or difficulty in accessibility of veins.
  • 10) A positive hepatitis screen (includes subtypes B \& C).
  • 11) A positive test result for antibody.
  • 12) Volunteer who had received a known drug within seven elimination half-life of the administered drug prior to the first dose of study medication.
  • 13) Volunteer who had donated blood or loss of blood 50 ml to 100 ml within 30 days or 101 ml to 200 ml within 60 days or >200 ml within 90 days (excluding volume drawn at screening for this study) prior to first dose of study medication, whichever was greater.
  • 14)Had history of difficulty in swallowing or of any gastrointestinal disease, which could affect drug absorption.
  • 15) Intolerance to venipuncture
  • 16) Any food allergy, intolerance, restriction or special diet that, in the opinion of the principal investigator or sub-investigator, could contraindicate the volunteer's participation in this study.
  • 17) Institutionalized volunteer.
  • 18) Used any prescribed medications within 14 days prior to the first dose of study medication.
  • 19) Used any OTC products, vitamin and herbal products, etc., within 7 days prior to the first dose of study medication.
  • 20) Used grapefruit and grapefruit containing products within 7 days prior to the first dose of study medication.
  • 21) Ingestion of any caffeine or xanthine products (i.e. coffee, tea, chocolate, and caffeine-containing sodas, colas, etc.), recreational drugs, alcohol or other alcohol containing products within 48 hours prior to the first dose of study medication.
  • 22) Ingestion of any unusual diet, for whatever reason (e.g.: low sodium) for three weeks prior to the first dose of study medication.
  • 23) Volunteer with WBC and less than lower limit of normal range.
  • 24) Volunteers with history of Psychosis, Suicidal thoughts and behavior or Stroke, (TIA), Seizure or any other related medical condition.
  • 25) Volunteers with more than 450 ms on ECG measurement at the time of screening.
  • 26) Sitting systolic blood pressure less than 110 mmHg or greater than 140 mmHg or sitting diastolic blood pressure less than 70 mmHg or greater than 90 mmHg and pulse rate less than 60 or greater than 100 beats per minute during screening.
  • 27) Volunteer had a personal or family history of dystonic reactions to medications.
  • 28)Had history of use of any neuroleptic drugs and illicit drugs.
  • 29)Had history of Hyperglycemia.
  • 30)Had history of Myocardial Infarction/ Ischaemic heart disease.
  • 31)Had history of Venous Thromboembolism.
  • 32)Had history of a known history of Extrapyramidal Symptoms (EPS).
  • 33)Had history of Dementia and Tardive Dyskinesia.
  • 34)Had history of Dysphagia.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Brexpiprazole Film Coated Tablets

    Brexpiprazole 4 mg Film Coated Tablets

    Drug: Brexpiprazole Film Coated Tablets · Drug: RXULTI film coated tablet

  • Active comparator
    RXULTI film coated tablet

    RXULTI 4 mg film coated tablet (Brexpiprazole)

    Drug: Brexpiprazole Film Coated Tablets · Drug: RXULTI film coated tablet

Interventions

  • 1 tablet of Brexpiprazole 4 mg Film Coated Tablets

  • DrugRXULTI film coated tablet

    1 tablet of RXULTI 4 mg film coated tablet (Brexpiprazole)

06

What researchers measure

Primary outcomes

  1. Maximum measured plasma concentration over the time span specified (Cmax)

    The 90% confidence interval of the relative mean (Geometric least square mean) of test to reference product for Ln-transformed Pharmacokinetic parameters Cmax

    Time frame: 72 hours

  2. Area under the plasma concentration-time curve from time point to the 72 hours (AUC72)

    The 90% confidence interval of the relative mean (Geometric least square mean) of test to reference product for Ln-transformed Pharmacokinetic parameters AUC72

    Time frame: 72 hours

Secondary outcomes

  1. Time of the maximum measured plasma concentration (Tmax)

    Descriptive Statistics

    Time frame: 72 hours

07

Study locations

1 site
  • Cliantha Research Limited
    Ahmedabad, Gujarat 382210, India
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Aug 2025, 1 month.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 1 month is below that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2025
First posted
Dec 5, 2025
StartActual
Jun 22, 2025
Primary completionActual
Aug 4, 2025
CompletionActual
Oct 7, 2025
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07266792
Responsible party
Sponsor
First posted
Dec 5, 2025
Start date
Jun 22, 2025
Primary completion
Aug 4, 2025
Completion
Oct 7, 2025
Last update
Dec 5, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion